Profile data is unavailable for this security.
About the company
Citius Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of first-in-class critical care products, with a pipeline of anti-infectives in oncology, adjunct cancer care, stem cell therapy and prescription products. The Company's FDA approved LYMPHIR candidate is a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Its late-stage pipeline also includes Mino-Lok, and CITI-002 (Halo-Lido). Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs) and central line associated bloodstream infections (CLABSIs). Halo-Lido is a topical formulation of halobetasol propionate, a corticosteroid, and lidocaine that is intended for the treatment of hemorrhoids. The Company is also seeking to develop and commercialize the NoveCite mesenchymal stem cells (NC-iMSCs) to treat acute respiratory conditions with a near term focus on ARDS.
- Revenue in USD (TTM)0.00
- Net income in USD-37.43m
- Incorporated2010
- Employees23.00
- LocationCitius Pharmaceuticals Inc11 Commerce Dr Fl 1CRANFORD 07016-3501United StatesUSA
- Phone+1 (908) 967-6677
- Websitehttps://www.citiuspharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fibrobiologics Inc | 0.00 | -18.50m | 16.94m | 13.00 | -- | 98.34 | -- | -- | -0.4809 | -0.4809 | 0.00 | 0.0026 | 0.00 | -- | -- | 0.00 | -192.59 | -- | -636.43 | -- | -- | -- | -- | -- | -- | -27.09 | 0.9734 | -- | -- | -- | 41.44 | -- | -- | -- |
| Klotho Neurosciences Inc | 0.00 | -11.29m | 16.96m | 3.00 | -- | 1.63 | -- | -- | -0.3264 | -0.3264 | 0.00 | 0.1411 | 0.00 | -- | -- | 0.00 | -180.10 | -- | -197.00 | -- | -- | -- | -- | -- | -- | -1.90 | 0.00 | -- | -- | -- | -556.89 | -- | -- | -- |
| Pasithea Therapeutics Corp | 0.00 | -13.49m | 17.02m | 4.00 | -- | 0.4494 | -- | -- | -5.21 | -5.21 | 0.00 | 1.64 | 0.00 | -- | -- | 0.00 | -83.64 | -- | -89.28 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 10.34 | -- | -- | -- |
| Linike Medical Group Ltd | 0.00 | -306.90k | 17.16m | -- | -- | -- | -- | -- | -0.1102 | -0.1102 | 0.00 | -0.153 | 0.00 | -- | -- | -- | -278.62 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -651.26 | -- | -- | -- |
| Lixte Biotechnology Holdings Inc | 0.00 | -4.13m | 17.45m | 2.00 | -- | 7.40 | -- | -- | -1.18 | -1.18 | 0.00 | 0.8612 | 0.00 | -- | -- | 0.00 | -114.55 | -113.03 | -130.06 | -121.30 | -- | -- | -- | -- | -- | -1,017.39 | 0.00 | -- | -- | -- | 29.51 | -- | -- | -- |
| Provectus Biopharmaceuticals Inc | 350.44k | -6.63m | 18.07m | 6.00 | -- | -- | -- | 51.57 | -0.0158 | -0.0158 | 0.0008 | -0.0146 | 0.5736 | -- | -- | 58,406.67 | -1,102.23 | -267.67 | -- | -- | -- | -- | -1,921.64 | -1,092.28 | -- | -27.00 | -- | -- | 10.66 | -- | -52.58 | -- | -- | -- |
| Apimeds Pharmaceuticals US Inc | 0.00 | -5.16m | 18.24m | 2.00 | -- | 2.23 | -- | -- | -0.4762 | -0.4762 | 0.00 | 0.6489 | 0.00 | -- | -- | 0.00 | -111.07 | -- | -138.71 | -- | -- | -- | -- | -- | -- | -162.30 | 0.0577 | -- | -- | -- | -78.73 | -- | -- | -- |
| Vyne Therapeutics Inc | 524.00k | -33.79m | 18.59m | 13.00 | -- | 0.5529 | -- | 35.47 | -0.7917 | -0.7888 | 0.0123 | 1.01 | 0.0093 | -- | -- | 40,307.69 | -60.16 | -107.54 | -70.67 | -136.47 | -- | -- | -6,448.47 | -1,720.83 | -- | -- | 0.00 | -- | 18.16 | -- | -42.82 | -- | 60.46 | -- |
| Citius Pharmaceuticals Inc | 0.00 | -37.43m | 18.67m | 23.00 | -- | 0.2405 | -- | -- | -3.84 | -3.84 | 0.00 | 3.74 | 0.00 | -- | -- | 0.00 | -32.10 | -29.86 | -52.00 | -35.19 | -- | -- | -- | -- | 0.1257 | -244.30 | 0.0127 | -- | -- | -- | 6.85 | -- | 400.55 | -- |
| Lunai Bioworks Inc | 0.00 | -130.98m | 18.98m | 29.00 | -- | -- | -- | -- | -7.51 | -7.51 | 0.00 | -0.5626 | 0.00 | -- | -- | 0.00 | -203.39 | -75.79 | -304.47 | -85.18 | -- | -- | -- | -- | -- | -28.85 | -- | -- | -- | -- | -101.31 | -- | -- | -- |
| IN8bio Inc | 0.00 | -20.66m | 19.43m | 18.00 | -- | 0.6924 | -- | -- | -6.48 | -6.48 | 0.00 | 2.87 | 0.00 | -- | -- | 0.00 | -126.22 | -79.60 | -150.81 | -91.19 | -- | -- | -- | -- | -- | -- | 0.0299 | -- | -- | -- | -1.43 | -- | -10.74 | -- |
| Anebulo Pharmaceuticals Inc | 0.00 | -8.44m | 19.50m | 2.00 | -- | 2.00 | -- | -- | -0.2354 | -0.2354 | 0.00 | 0.237 | 0.00 | -- | -- | 0.00 | -128.22 | -108.15 | -145.11 | -112.69 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -3.45 | -- | -- | -- |
| LeonaBio Inc | 0.00 | -37.72m | 19.72m | 26.00 | -- | 0.7362 | -- | -- | -9.68 | -9.68 | 0.00 | 6.79 | 0.00 | -- | -- | 0.00 | -64.88 | -36.31 | -87.99 | -38.92 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 17.62 | -- | -- | -- |
| Serina Therapeutics Inc | 130.00k | -18.59m | 19.84m | 12.00 | -- | -- | -- | 152.58 | -1.88 | -1.88 | 0.0133 | 0.1669 | 0.0131 | -- | -- | 10,833.33 | -187.74 | -188.54 | -- | -- | -- | -- | -14,331.54 | -7,513.03 | -- | -730.13 | 0.6444 | -- | -60.56 | -49.64 | 24.74 | -- | -49.05 | -- |
| Oncotelic Therapeutics Inc | 0.00 | -1.67m | 19.87m | 26.00 | -- | 2.18 | -- | -- | -0.0041 | -0.0041 | 0.00 | 0.0206 | 0.00 | -- | -- | 0.00 | -7.00 | -20.78 | -19.04 | -43.80 | -- | -- | -- | -1,590.30 | -- | -0.5591 | 0.632 | -- | -100.00 | -- | 42.76 | -- | -- | -- |
| Hi-Great Group Holding Co | 48.03k | -64.27k | 20.34m | -- | -- | -- | -- | 423.44 | -0.0006 | -0.0006 | 0.0005 | -0.002 | 0.7229 | 0.5559 | -- | -- | -96.73 | -21.81 | -- | -256.35 | 38.77 | 45.63 | -133.81 | -21.02 | 0.0288 | -- | -- | -- | -36.79 | -- | 60.07 | -- | -- | -- |
Data as of Feb 12 2026. Currency figures normalised to Citius Pharmaceuticals Inc's reporting currency: US Dollar USD
9.82%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Heights Capital Management, Inc.as of 20 Oct 2025 | 1.46m | 7.03% |
| Geode Capital Management LLCas of 30 Sep 2025 | 119.77k | 0.58% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 119.72k | 0.58% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 77.76k | 0.37% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 69.85k | 0.34% |
| UBS Securities LLCas of 31 Dec 2025 | 68.17k | 0.33% |
| Susquehanna Financial Group LLLPas of 30 Sep 2025 | 48.19k | 0.23% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 2025 | 27.03k | 0.13% |
| NewEdge Advisors LLCas of 30 Sep 2025 | 25.40k | 0.12% |
| SSgA Funds Management, Inc.as of 30 Sep 2025 | 23.27k | 0.11% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
